Mutual Funds Sahi Hai!
To avail the service, you will be redirected to loans.geojitcredits.com
Sun Pharmaceutical Industries announced that UNLOXCYT® (cosibelimab-ipdl) has been elevated to a National Comprehensive Cancer Network® (NCCN®) Category 2A recommended option for patients with locally advanced cutaneous squamous cell carcinoma (laCSCC) who are not candidates for curative surgery or curative radiation.
This is an addition to the Category 2A designation in metastatic cutaneous squamous cell carcinoma (mCSCC), which was assigned to UNLOXCYT in 2025.
UNLOXCYT was approved by the U.S. Food and Drug Administration (FDA) in 2024 and is indicated for the treatment of adults with mCSCC or laCSCC who are not candidates for curative surgery or curative radiation. The recommended dosage of UNLOXCYT is 1,200 mg as an intravenous infusion over 60 minutes every 3 weeks. UNLOXCYT is the first and only FDA approved PD-L1-blocking antibody for advanced CSCC (aCSCC).
The evidence submitted to NCCN in support of the change was based on the pivotal registration study, in which 55% of patients achieved an objective response, including 26% who achieved a complete response. Responses were durable: at a median follow-up of 24.1 months; median duration of response had not been reached (range: 8.3 to 31.3+ months). In addition, fewer than 1% of patients experienced a high-grade (Grade 3-5) immune-mediated adverse reaction (imARs)—an important consideration in this patient population. There were no grade 4 or 5 imARs.
NCCN is an alliance of 34 leading cancer centers in the U.S. Its Clinical Practice Guidelines in Oncology, referred to as the NCCN Guidelines, provide recommendations for the prevention, diagnosis, evaluation, and treatment of different types of cancer. The NCCN Guidelines are among the most influential clinical guidelines in cancer care, offering evidence-based, expert developed recommendations intended to help clinicians make treatment decisions for patients with cancer.
CreditAccess Grameen Ltd, Sun Pharmaceutical Industries Ltd, Bharti Hexacom Ltd, Page Industries Ltd are among the other stocks to see a surge in volumes on BSE today, 21 October 2026.
L&T Technology Services Ltd recorded volume of 3.07 lakh shares by 10:45 IST on BSE, a 38.53 times surge over two-week average daily volume of 7976 shares. The stock gained 10.85% to Rs.4,001.55. Volumes stood at 6411 shares in the last session.
CreditAccess Grameen Ltd recorded volume of 2.11 lakh shares by 10:45 IST on BSE, a 19.13 times surge over two-week average daily volume of 11010 shares. The stock lost 3.37% to Rs.1,185.25. Volumes stood at 4791 shares in the last session.
Sun Pharmaceutical Industries Ltd clocked volume of 2.82 lakh shares by 10:45 IST on BSE, a 3.8 times surge over two-week average daily volume of 74100 shares. The stock lost 0.40% to Rs.1,738.05. Volumes stood at 39660 shares in the last session.
Bharti Hexacom Ltd witnessed volume of 1.63 lakh shares by 10:45 IST on BSE, a 3.73 times surge over two-week average daily volume of 43589 shares. The stock increased 2.17% to Rs.1,667.70. Volumes stood at 1.1 lakh shares in the last session.
Page Industries Ltd registered volume of 5526 shares by 10:45 IST on BSE, a 3.35 fold spurt over two-week average daily volume of 1651 shares. The stock slipped 1.01% to Rs.35,343.00. Volumes stood at 10223 shares in the last session.
Sun Pharmaceutical Industries and LIB Therapeutics Inc. (LIB) today announced:
Lerodalcibep is approved in the EU under the brand name Lyrokaul for the treatment of adult patients with hypercholesterolaemia and mixed dyslipidaemia. In the United States, it is US FDA-approved under the brand name Lerochol as an adjunct to diet and exercise: to reduce low-density lipoprotein cholesterol (LDL-C) in adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia (HeFH).
The partnership helps address a significant global unmet need in cardiovascular care. Many patients at high or very high cardiovascular risk remain above recently updated and more globally harmonized 2026 guideline recommended LDL-cholesterol (LDL-C) goals despite treatment. In the DA VINCI observational study across 18 European countries, only 33% of patients assessed on stable oral lipid-lowering therapy achieved their risk-based 2019 European Society of Cardiology/European Atherosclerosis Society (ESC/EAS) LDL-C goals.
Treatment guidelines now emphasise both additional LDL-C reductions and lower targets for patients at high and very high cardiovascular risk, with additional therapies when statins alone are insufficient. PCSK9 inhibitors provide the efficacy and safety to achieve these goals.4 This gap between treatment goals and real-world control reinforces the opportunity for Sun Pharma and LIB to broaden access to innovative lipid-lowering care across Europe and Sun's world-wide licensed markets.
The agreement establishes a significant new growth platform for Sun Pharma in a large and rapidly expanding market. According to IQVIA, the PCSK9 inhibitor market outside the United States and China reached US$ 3.7 billion in the period ending Q2 2026 (MAT Q2 2026), growing at 38% CAGR over the preceding two years. Europe alone accounted for US$ 2.9 billion PCSK9 inhibitor market in MAT Q2 2026.
LIB will receive an upfront and future milestone payments, together with royalties based on net sales in the licensed territories. Other terms of the agreement are confidential. Sun Pharma will be responsible for pursuing regulatory approvals in licensed territories where approval has not yet been obtained.
Sun Pharmaceutical Industries Ltd fell for a fifth straight session today. The stock is quoting at Rs 1873.4, down 0.66% on the day as on 13:19 IST on the NSE. The benchmark NIFTY is down around 0.4% on the day, quoting at 23541.1. The Sensex is at 75140.89, down 0.58%.Sun Pharmaceutical Industries Ltd has eased around 3.65% in last one month.Meanwhile, Nifty Pharma index of which Sun Pharmaceutical Industries Ltd is a constituent, has increased around 0.92% in last one month and is currently quoting at 26880.8, down 0.59% on the day. The volume in the stock stood at 6.8 lakh shares today, compared to the daily average of 15.37 lakh shares in last one month.
The benchmark September futures contract for the stock is quoting at Rs 1883.1, down 0.75% on the day. Sun Pharmaceutical Industries Ltd jumped 17.57% in last one year as compared to a 5.73% slide in NIFTY and a 20.8% spurt in the Nifty Pharma index.
The PE of the stock is 141.76 based on TTM earnings ending June 26.
Sun Pharmaceutical Industries and certain of its subsidiaries have been defendants in antitrust litigation in the United States relating to a 2008 patent litigation settlement agreement with Pfizer concerning generic Lipitor (Atorvastatin).
Plaintiffs alleged that the settlement unlawfully delayed generic competition for Lipitor and that absent the unlawful settlement, Lipitor would have entered the market earlier than it did.
The matter has been disclosed from time to time in the Company's financial statements.
The United States Court of Appeals for the Third Circuit has affirmed the order of the United States District Court granting summary judgment in its entirety in favour of the Company and its subsidiaries.
The Appellate Court has also affirmed the District Court's orders denying class certification as to the plaintiffs.
This decision represents a significant favourable development for the Company and its subsidiaries in the matter, and brings the litigation substantially to a close, subject to any further remedies that may be available to the plaintiffs under applicable law.